What are you searching for?

Sign in
Breaking News, Promotions & Moves

Flexion Therapeutics Appoints CFO

David Arkowitz brings more than 25 years of experience in the life sciences and biotechnology industries

Flexion Therapeutics announced that David Arkowitz has been named chief financial officer. Mr. Arkowitz brings more than 25 years of finance and operations leadership experience in the life sciences and biotechnology industries.

 
“I am delighted to have David come on board at such an important point in the company’s evolution,” said Michael Clayman, M.D., president and chief executive officer of Flexion. “David has impeccable credentials, bringing deep business acumen, outstanding leadership skills and broad commercial experience to this key role. I am confident that he will factor centrally in our future success, and we are very fortunate to have him join us.”
 
“Flexion is a remarkable company with impressive leadership, a disruptive flagship product and promising growth potential,” said Mr. Arkowitz. “I am honored and excited to be joining the team at this pivotal time, and I look forward to bringing my skills to bear to achieve great things for patients, our employees and shareholders.”
 
Prior to joining Flexion, Mr. Arkowitz served as chief operating officer and chief financial officer at Visterra, Inc., where he led the finance, business development, corporate planning, and other functions. 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters